Techcyte and Cytobay Partner to Create Non-Invasive Digital Diagnostic Test for Bladder Cancer
OREM, UT, UNITED STATES, May 26, 2022 /EINPresswire.com/ -- Bladder cancer is one of the most common cancers and has a high recurrence rate. After successful treatment, it is recommended that survivors be tested every three to six months for the first …